



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034
STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS PERIOD
ENDED 31st Dec ' 2019.

PART - I		(Rs. In Lakhs)					
		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un- Audited	Audited	Un-Audited	un- Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)**	(6)**
1	Income						
	Revenue from operations	17,870.62	27,292.76	12,691.52	64,902.52	12,691.52	37,783.46
	Other Income	488.75	544.52	18.57	1,277.73	18.57	60.01
	Total income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
2	Expenses						
	a) Cost of materials consumed	5,686.20	6,047.63	6,217.04	17,600.14	6,217.04	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,303.88)	3,057.82	(3,434.32)	21.80	(3,434.32)	(2,132.13)
	d) Employee benefits expense	1,756.68	1,742.23	1,335.38	5,420.05	1,335.38	2,963.15
	e) Finance costs	717.56	399.11	104.58	1,460.89	104.58	278.92
	f) Depreciation and amortisation expense	559.94	562.29	554.01	1,680.67	554.01	1,149.68
	g) Manufacturing Exps	2,707.32	2,680.40	2,657.37	7,931.62	2,657.37	5,130.47
	h) R & D Exps	-	-	-	-	-	-
	i) Other Expenses	1,058.35	1,207.28	961.95	3,150.02	961.95	2,214.55
	Total expenses	11,182.17	15,696.76	8,396.01	37,265.19	8,396.01	22,056.76
3	Profit before exceptional items & Tax (1-2)	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
6	Tax Expenses						
	a) Current tax	1,962.27	3,140.18	880.26	7,531.87	880.26	3,317.07
	b) Deferred tax	15.08	8.76	(11.31)	(300.76)	(11.31)	1,542.21
7	Net Profit/ (Loss) for the period/year (5-6)	5,199.85	8,991.58	3,445.13	21,683.95	3,445.13	10,927.43
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(82.35)	(4.23)	-	(90.81)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	19.90	1.48	-	22.86	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(62.45)	(2.75)	-	(67.95)	-	-
9	Total Comprehensive Income for the period (7+8)	5,137.40	8,988.83	3,445.13	21,616.00	3,445.13	10,927.43
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	57,756.22
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	4.09	7.06	2.71	17.04	2.71	8.59
	b) Diluted	4.09	7.06	2.71	17.04	2.71	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



PART - II		(Rs. In Lakhs)					
		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un- Audited	Audited	Un-Audited	un- Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)**	(6)**
1	Income						
	Revenue from operations	17,870.62	27,292.76	12,691.52	64,902.52	12,691.52	37,783.46
	Other Income	488.75	544.52	18.57	1,277.73	18.57	60.01
	Total income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
2	Expenses						
	a) Cost of materials consumed	5,686.20	6,047.63	6,217.04	17,600.14	6,217.04	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress	(1,303.88)	3,057.82	(3,434.32)	21.80	(3,434.32)	(2,132.13)
	d) Employee benefits expense	1,756.68	1,742.23	1,335.38	5,420.05	1,335.38	2,963.15
	e) Finance costs	760.55	442.40	104.58	1,584.85	104.58	278.92
	f) Depreciation and amortisation	559.94	562.29	554.01	1,680.67	554.01	1,149.68
	g) Manufacturing Exps	2,707.32	2,680.40	2,657.37	7,931.62	2,657.37	5,130.47
	h) R & D Exps	-	-	-	-	-	-
	i) Other Expenses	1,059.75	1,207.28	961.95	3,152.45	961.95	2,214.55
	Total expenses	11,226.56	15,740.05	8,396.01	37,391.58	8,396.01	22,056.76
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	7,132.81	12,097.23	4,314.08	28,788.67	4,314.08	15,786.71
4	Add : Share of profit/(Loss) of Associates.	635.58	352.19	-	2,724.38	-	-
5	Profit before exceptional items , Tax (3+4)	7,768.39	12,449.42	4,314.08	31,513.05	4,314.08	15,786.71
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	7,768.39	12,449.42	4,314.08	31,513.05	4,314.08	15,786.71
8	Tax Expenses						
	a) Current tax	1,962.27	3,140.18	880.26	7,531.87	880.26	3,317.07
	b) Deferred tax	15.08	8.76	(11.31)	(300.76)	(11.31)	1,542.21
9	Net Profit/ (Loss) for the period/year(7-8)	5,791.04	9,300.48	3,445.13	24,281.94	3,445.13	10,927.43
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(82.35)	(4.23)	-	(90.81)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	19.90	1.48	-	22.86	-	-
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(62.45)	(2.75)	-	(67.95)	-	-
11	Total Comprehensive Income for the period (9 + 10)	5,728.59	9,297.73	3,445.13	24,213.99	3,445.13	10,927.43
12	Paid-up equity share capital Face Value of the Share	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00
13	Other Equity	-	-	-	-	-	57,756.22
14	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	4.55	7.31	2.71	19.08	2.71	8.59
	b) Diluted	4.55	7.31	2.71	19.08	2.71	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



NOTES:-1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 13th Feb,2020 and the same has been reviewed by the Statutory Auditors.

2) This is the first financial results of the Company published in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended 31st December,2019 (pending for listing of 127,282,478 fully paid equity shares of Rs. 1 each of the Company on BSE Limited (BSE) and National Stock Exchange of India (NSE)). The aforesaid shares were allotted at par in terms of the Composite Scheme of Arrangement ('the Scheme') on 27th January, 2020 for an aggregated sum of Rs. 1,272.82 Lakhs, earlier credited to equity share suspense and since then transferred to equity share capital.

3) Consequent to the demerger of Demerged Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October,2018, the financial results for the nine months ended 31st December,2019 are not comparable with the previous corresponding period. Further, for the purpose of calculating earnings per share for the year ended 31st March,2019, the equity shares issued pursuant to the Scheme have been considered effective as on 1st October,2018 and the equity shares of the Company outstanding stand cancelled from the aforesaid date.

4)** The figures for the year ended 31st March,2019 and Period ended 31st December ,2018 represent figures from 1st October,2018(Appointed date of demerger of Demerged Undertaking into the

5) The Company is engaged in the business of Pharmaceuticals Manufacturing & Services . Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

6) The Company elected to exercise the option permitted u/s 115BAA of the Income tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the nine months ended December 31, 2019 and re-measured its Deferred Tax Liability on the basis of the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the Period ended December 31, 2019.

7) The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quaterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com .

8) As the company has invested in Suven Pharma Inc(WOS) during April,2019, the consolidated figures for the Qtr&period ended 31/12/2019&year ended 31/03/2019 are same as standalone .

9) The Board has declared an Interim Dividend of Rs.2.50 per equity share (250% of face value of Rs. 1.00/- each)and a one time special dividend of Rs.2.50(250% of face value of Rs.1.00 each) totalling to Rs.5.00 per share (500% of face value of Rs.1.00 each) post demerger of Suven's Pharmaceuticals mfg & Services business for the financial year 2019-20.

10) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : 13th Feb ' 2020



For SUVEN PHARMACEUTICALS LTD

Venkat Jasti

VENKAT JASTI

Chairman & MD

DIN: 00278028